Literature DB >> 29663951

Active case finding and treatment adherence in risk groups in the tuberculosis pre-elimination era.

R K Gupta1, M Lipman2, A Story3, A Hayward4, G de Vries5, R van Hest6, C Erkens7, M X Rangaka1, I Abubakar1.   

Abstract

Vulnerable populations, including homeless persons, high-risk drug and alcohol users, prison inmates and other marginalised populations, contribute a disproportionate burden of tuberculosis (TB) cases in low-incidence settings. Drivers of this disease burden include an increased risk of both TB transmission in congregate settings, and progression from infection to active disease. Late diagnosis and poor treatment completion further propagate the epidemic and fuel the acquisition of drug resistance. These groups are therefore a major priority for TB control programmes in low-incidence settings. Targeted strategies include active case finding (ACF) initiatives and interventions to improve treatment completion, both of which should be tailored to local populations. ACF usually deploys mobile X-ray unit screening, which allows sensitive, high-throughput screening with immediate availability of results. Such initiatives have been found to be effective and cost-effective, and associated with reductions in proxy measures of transmission in hard-to-reach groups. The addition of point-of-care molecular diagnostics and automated X-ray readers may further streamline the screening pathway. There is little evidence to support interventions to improve adherence among these risk groups. Such approaches include enhanced case management and directly observed treatment, while video-observed therapy (currently under evaluation) appears to be a promising tool for the future. Integrating outreach services to include both case detection and case-management interventions that share a resource infrastructure may allow cost-effectiveness to be maximised. Integrating screening and treatment for other diseases that are prevalent among targeted risk groups into TB outreach interventions may further improve cost-effectiveness. This article reviews the existing literature, and highlights priorities for further research.

Entities:  

Mesh:

Year:  2018        PMID: 29663951     DOI: 10.5588/ijtld.17.0767

Source DB:  PubMed          Journal:  Int J Tuberc Lung Dis        ISSN: 1027-3719            Impact factor:   2.373


  7 in total

1.  Potential to Use Fingerprints for Monitoring Therapeutic Levels of Isoniazid and Treatment Adherence.

Authors:  Mahado Ismail; Catia Costa; Katherine Longman; Mark A Chambers; Sarah Menzies; Melanie J Bailey
Journal:  ACS Omega       Date:  2022-04-21

2.  Delays in diagnosing pulmonary tuberculosis within a context of medium incidence, Medellín, Colombia, 2017: an operational research.

Authors:  Iader Rodríguez-Márquez; Fernando Montes; Luz D Upegui; Nilton Montoya; Nelly E Vargas; Abelardo Rojas; Gloria C Valencia; Claudia M Álvarez; Leonardo Uribe; Jesús Ochoa
Journal:  BMC Public Health       Date:  2020-05-24       Impact factor: 3.295

3.  Active versus passive case finding for tuberculosis in marginalised and vulnerable populations in India: comparison of treatment outcomes.

Authors:  Hemant Deepak Shewade; Vivek Gupta; Srinath Satyanarayana; Sunil Kumar; Prabhat Pandey; U N Bajpai; Jaya Prasad Tripathy; Soundappan Kathirvel; Sripriya Pandurangan; Subrat Mohanty; Vaibhav Haribhau Ghule; Karuna D Sagili; Banuru Muralidhara Prasad; Priyanka Singh; Kamlesh Singh; Gurukartick Jayaraman; P Rajeswaran; Moumita Biswas; Gayadhar Mallick; Ali Jafar Naqvi; Ashwin Kumar Bharadwaj; K Sathiyanarayanan; Aniruddha Pathak; Nisha Mohan; Raghuram Rao; Ajay M V Kumar; Sarabjit Singh Chadha
Journal:  Glob Health Action       Date:  2019       Impact factor: 2.640

4.  Validation of Differentially Expressed Immune Biomarkers in Latent and Active Tuberculosis by Real-Time PCR.

Authors:  Prem Perumal; Mohamed Bilal Abdullatif; Harriet N Garlant; Isobella Honeyborne; Marc Lipman; Timothy D McHugh; Jo Southern; Ronan Breen; George Santis; Kalaiarasan Ellappan; Saka Vinod Kumar; Harish Belgode; Ibrahim Abubakar; Sanjeev Sinha; Seshadri S Vasan; Noyal Joseph; Karen E Kempsell
Journal:  Front Immunol       Date:  2021-03-16       Impact factor: 7.561

5.  Tuberculosis Surveillance in Romania Among Vulnerable Risk Groups Between 2015 and 2017.

Authors:  Ioana Munteanu; Nicoleta Cioran; Rob van Hest; Ibrahim Abubakar; Alistair Story; Domnica Chiotan; Gerard de Vries; Beatrice Mahler
Journal:  Ther Clin Risk Manag       Date:  2022-04-20       Impact factor: 2.755

6.  The cost-effectiveness of an HCV outreach intervention for at-risk populations in London, UK.

Authors:  Zoe Ward; Linda Campbell; Julian Surey; Steven Platts; Rachel Glass; Matthew Hickman; Alistair Story; Peter Vickerman
Journal:  J Antimicrob Chemother       Date:  2019-11-01       Impact factor: 5.790

Review 7.  Relational Dynamics of Treatment Behavior Among Individuals with Tuberculosis in High-Income Countries: A Scoping Review.

Authors:  Marc C I Lipman; Karina Kielmann; Stella Arakelyan; Aaron S Karat; Annie S K Jones; Nicole Vidal; Helen R Stagg; Marcia Darvell; Robert Horne
Journal:  Patient Prefer Adherence       Date:  2021-09-21       Impact factor: 2.711

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.